

Targeted therapies for Ovarian Cancer

Grunewald T¹ & Ledermann JA^{1,2}

¹University College London Hospitals and ²UCL Cancer Institute, London, UK

correspondence:

Prof Jonathan A Ledermann

Cancer Research UK and UCL Cancer Trials Centre

UCL Cancer Institute

90 Tottenham Court Road,

London W1T 4JT

UK

j.ledermann@ucl.ac.uk

Abstract:

1
2
3
4
5 Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies.
6
7 Most women present with advanced disease and develop a recurrence after radical surgery
8
9 and chemotherapy. Improving the results of first- or subsequent line chemotherapy has been
10
11 slow and novel approaches to systemic treatment are needed. Ovarian cancer is a
12
13 heterogeneous disease with complex molecular and genetic changes. Understanding these
14
15 better will provide information on the mechanisms of resistance and opportunities to target
16
17 therapy more rationally, exploiting specific changes in the tumour. Here we review targeted
18
19 approaches to therapy, focussing on targeting angiogenesis and inhibition of DNA repair, two
20
21 areas that show promising activity. Additionally, we review studies that are underway
22
23 targeting the cell cycle and signalling pathways as well as immunotherapeutic strategies.
24
25 Many of these innovative approaches already demonstrate promising activity in ovarian
26
27 cancer, and have the potential to improve the outcome in women with ovarian cancer.
28
29
30
31
32
33
34
35

36 **Keywords: targeted therapy, ovarian cancer, anti-angiogenesis, PARP inhibitor,**
37
38 **immunotherapy**
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction:

1
2
3
4
5 Epithelial ovarian cancer (EOC) is one of the most common gynaecological malignancies and
6
7 most women present with advanced disease. It has a high mortality rate and is the 5th most
8
9 common cause of cancer death in women [1]. Whilst the survival of patients with advanced
10
11 ovarian cancer has increased over the last two decades through better surgery and more
12
13 chemotherapy options, cytotoxic drug therapy has been non-selective often resulting in
14
15 significant toxicity and short-lived anti-tumour responses. Most women with ovarian cancer
16
17 will suffer a tumour recurrence after first-line therapy and in almost all of them, resistance to
18
19 chemotherapy will eventually develop leading to death from ovarian cancer. There has been a
20
21 significant increase in the knowledge of molecular and genetic changes in ovarian, and this
22
23 has led to the development and evaluation of targeted therapies in this disease. Here we
24
25 review how these new drugs are being used and investigated in women with ovarian cancer,
26
27 and their contribution thus far to improving the response to therapy and disease outcome.
28
29
30
31
32
33
34
35

1. Angiogenesis

36
37
38
39
40
41 Solid tumour growth and progression is reliant on neovascularisation [2]. Angiogenesis is
42
43 complex and is regulated by several different endogenous pro-angiogenic and anti-angiogenic
44
45 factors. Key angiogenic molecules include vascular endothelial growth factor (VEGF),
46
47 platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and angiopoietin (Ang
48
49 1 and 2) [3]. The Ang 1/2 –Tie 2 receptor axis is a VEGF independent signalling pathway,
50
51 which mediates vascular re-modelling [3]. Folkman et al proposed that a fine balance exists
52
53 between angiogenic inhibitory and stimulatory factors. In normal tissues angiogenesis is
54
55 turned off. However, an '*angiogenic switch*' can occur in tumours leading to the production
56
57
58
59
60
61
62
63
64
65

1 of pro-angiogenic stimuli causing growth of the tumour and its vasculature [4]. These new
2 blood vessels often have defective basement membranes, are thin walled and leaky, allowing
3 cancer cells to enter the circulation and metastasise [5].
4
5
6

7
8
9 In EOC, angiogenesis plays a role in tumour growth, formation of ascites and metastasis.

10
11 The vasculature within the tumour is more structurally and functionally abnormal, with
12 tortuous, leaky, dilated and immature blood vessels with poor flow. The endothelial cells
13 within these vessels are more dependent on VEGF for survival when compared to more
14 mature blood vessels elsewhere in the body [6].
15
16
17
18
19
20
21
22
23

24 The VEGF family of growth factors and its receptors are the most important signalling
25 pathways in tumour angiogenesis [6]. VEGF-A is the best-characterised VEGF ligand and
26 appears to play a dominant role in angiogenesis by binding to VEGF receptor tyrosine
27 kinases (VEGFR). In angiogenesis the two most important members of the VEGFR family
28 are VEGFR1 (Flt-1) and VEGFR2 (Flk-1). VEGFR2 has the most direct effect on
29 angiogenesis, by mediating the angiogenic and permeability enhancing effects of VEGF. The
30 role of VEGFR1 is less direct, and may play a role in angiogenesis by recruiting bone
31 marrow derived cells and monocytes into the tumour vasculature [7].
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **2. Vascular Endothelial Growth Factor (VEGF) inhibition**

47
48
49
50

51 Inhibition of VEGF restores the balance between pro-angiogenic and anti-angiogenic factors,
52 thereby normalising tumour blood vessel structure and function [8]. This influences tumour
53 growth and is thought to improve the delivery of chemotherapy drugs to tumours and to
54 decrease their metastatic potential.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

There is a high expression of VEGFR in ovarian cancer and many tumours produce high levels of VEGF. Inhibitors of VEGF signalling such as the recombinant monoclonal antibody, bevacizumab that binds to circulating VEGF-A and aflibercept, a fusion protein that binds directly to VEGF preventing it from binding to its receptors, have been extensively evaluated in ovarian cancer treatment. Another strategy that has been explored is to use a peptide-Fc fusion protein, trebananib, which binds to Ang 1 and Ang 2, preventing its interaction with the Tie 2 receptor [3].

2.1 Bevacizumab

In ovarian cancer, bevacizumab has been explored as a single agent, in combination with chemotherapy, and as maintenance treatment post chemotherapy. It has been studied extensively in the setting of first-line platinum-based chemotherapy, ‘platinum-sensitive’ (relapse > 6months following completion of platinum based treatment) and in ‘platinum-resistant’ disease (relapse \leq 6 months of completing platinum based treatment). For a summary the pivotal trials described below see table 1.

ICON7 [9] and GOG 218 [10] are the two key first-line studies investigating the addition of bevacizumab to chemotherapy following surgery for advanced ovarian cancer. In ICON7, patients were randomised to standard 6 cycles of three-weekly carboplatin and paclitaxel with or without intravenous bevacizumab 7.5mg/kg every three weeks followed by maintenance bevacizumab for up to 12 months. The median progression free survival (PFS) was 17.5 months with standard therapy alone versus 19.9 months in the bevacizumab arm (HR 0.87; p=0.04). The benefit from bevacizumab was greater in women at higher risk of progression due to incomplete cytoreductive surgery (\geq 1 cm residual disease) or FIGO stage IV disease.

1 In this group the PFS was 14.5 compared to 18.1 months in women receiving bevacizumab.
2 No difference was seen in the median overall survival (OS), which was 58 months. However,
3
4 in the higher risk subgroup there was a 9.5 month difference in the median OS, 30.2 vs 39.7
5
6 months (p=0.03) in women receiving bevacizumab [11]. The second trial GOG 218 was a
7
8 US-led 3-arm randomised placebo-controlled study. Each arm received 6 cycles of standard
9
10 three-weekly carboplatin and paclitaxel. Arm 1 received chemotherapy with placebo, and
11
12 placebo maintenance for 15 months, arm 2 chemotherapy plus bevacizumab (15mg/kg) from
13
14 cycle 2-6 then switching to placebo maintenance as above, and women in arm 3 received
15
16 chemotherapy plus bevacizumab from cycle 2-6 followed by bevacizumab maintenance.
17
18 Compared to the control (arm 1) a significant improvement in PFS was seen only in women
19
20 receiving bevacizumab with chemotherapy and as maintenance. The difference in median
21
22 PFS in this group compared to placebo was 3.9 months and there was no difference in OS
23
24 (table 1 for details) [10].
25
26
27
28
29
30
31
32
33

34 In women with 'platinum-sensitive' recurrent disease, the OCEANS trial [12] evaluated the
35
36 addition of bevacizumab to chemotherapy and then as maintenance post chemotherapy until
37
38 disease progression. Patients were randomised to three-weekly chemotherapy (gemcitabine
39
40 1000mg/m² D1,8 and carboplatin AUC 4) with bevacizumab 15mg/kg or placebo. A 4 month
41
42 improvement in median PFS was seen that was statistically significant, but there was no OS
43
44 benefit [13]. Similar results were seen in GOG 0213 that compared three-weekly carboplatin
45
46 and paclitaxel with or without bevacizumab. In this trial there was a 3.4 month significant
47
48 difference in median PFS. Preliminary results reported a trend towards an improvement in
49
50 median OS and the benefit was unaffected by prior use of bevacizumab [14].
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 In women with 'platinum-resistant' relapse, the phase III randomised AURELIA trial [15]
2 evaluated the addition of bevacizumab to a choice of chemotherapy regimens (weekly
3 paclitaxel, pegylated liposomal doxorubicin [PLD] or topotecan, given either over five days,
4 or weekly). Overall, there was a 3.3month improvement in median PFS when bevacizumab
5 was added to chemotherapy which was significant (table 1). Bevacizumab was not continued
6 as maintenance therapy but the benefit in PFS and quality of life was seen consistently across
7 all subgroups, particularly in patients with ascites, which is associated with a poorer
8 prognosis [16]. The greatest difference in PFS was seen in patients receiving weekly
9 paclitaxel [17]. There was no statistically significant improvement in OS but the trial was not
10 designed to show a difference in OS and 40% of patients receiving chemotherapy alone were
11 subsequently treated with bevacizumab.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Toxicities of VEGF-Inhibitors include hypertension, impaired wound healing, proteinuria,
30 increase risk of thromboembolism and gastrointestinal toxicities. This includes the rare but
31 serious complications of perforation and fistulae and a decision to use bevacizumab needs to
32 take note of the volume of serosal disease, particularly thickening of the sigmoid colon due to
33 tumour, as the risk of perforation is greater in patients with large amounts of serosal disease.
34
35
36
37
38
39
40
41
42
43

44 Despite evidence of activity in different phases of the treatment pathway, there is no
45 international consensus about when the value of bevacizumab therapy is greatest. This is
46 reflected in the license, with indications varying across the world.
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.2 Aflibercept

1
2
3
4
5 Intravenous aflibercept has been evaluated in recurrent ovarian cancer both as a single agent
6
7 and in combination with chemotherapy. In ‘platinum-resistant’ disease the response rate to
8
9 single-agent aflibercept is <5% [18], although in combination with docetaxel, the response
10
11 rate has been reported to be 54%. However, these patients were not as heavily pre-treated as
12
13 those enrolled in the single agent phase II study and 13/46 (28%) patients had ‘platinum-
14
15 sensitive’ disease [19]. Aflibercept prolongs the time to repeat paracentesis in women with
16
17 recurrent symptomatic ascites, when compared to placebo, with a median time to repeat
18
19 paracentesis of 55.1 days and 31.8 days respectively [20]. However, the risk of fatal bowel
20
21 perforation is increased with aflibercept and the risk-benefit balance needs to be carefully
22
23 considered [20].
24
25
26
27
28
29
30

2.3 Trebananib

31
32
33
34
35
36 Trebananib has been evaluated in a series of trials: TRINOVA-1, a randomised phase III trial
37
38 combining trebananib with weekly paclitaxel in 919 women with recurrent ovarian cancer
39
40 relapsing after a platinum-free interval of <12 months. Compared to placebo, trebananib
41
42 significantly prolonged the median PFS (7.2 vs 5.4 months respectively; HR 0.66; p<0.0001)
43
44 but no OS advantage was seen (19.3 vs 18.3 months; HR 0.95; p=0.55). The main toxicity
45
46 observed was oedema [21]. Results from two other phase III studies of trebananib in ovarian
47
48 cancer are pending; TRINOVA-2 (NCT01281254) a study of PLD with or without trebananib
49
50 also in recurrent ovarian cancer, and TRINOVA-3 (NCT01493505) a study in which
51
52 trebananib was combined with first-line chemotherapy.
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Multi-targeted anti-angiogenic agents

1
2
3
4 Tyrosine kinase inhibitors (TKIs) are multi-targeted, low-molecular weight drugs, which bind
5 to the ATP-binding catalytic site of the tyrosine kinase domains of VEGF-R and other
6
7 tyrosine kinases. These oral agents often target more than one receptor tyrosine kinase [4].
8
9 Examples include sorafenib, cediranib, pazopanib and nintedinib, all of which have been
10
11 shown to have activity in ovarian cancer [3]. It is attractive to use a drug that targets more
12
13 than one pathway, as this could lead to a greater inhibition of angiogenesis compared with
14
15 single pathway inhibitors such as bevacizumab. However, while the therapeutic response
16
17 may be greater, their more complex mechanism of action may increase toxicity [4] (table 2).
18
19
20
21
22
23
24
25

3.1 Pazopanib

26
27
28
29
30
31 Pazopanib targets several angiogenic receptors including downstream signals of VEGFR
32
33 1,2,3, PDGFR and c-kit [22, 23]. Pazopanib has been evaluated in recurrent ovarian cancer
34
35 and as maintenance therapy in the first-line setting. In MITO11 [24], an open-label phase II
36
37 trial, patients with ‘platinum-resistant’ ovarian cancer were randomised to weekly paclitaxel
38
39 with or without pazopanib. There was a 2.9 month improvement in PFS in the combination
40
41 arm (median 6.3 vs 3.4 months) that was statistically significant. In the phase III study,
42
43 AGO-OVAR-16, patients who did not have tumour progression at the end of first-line
44
45 therapy, were randomised to maintenance pazopanib or placebo for up to 24 months. There
46
47 was an improvement of 5.6 months in the median PFS in patients on pazopanib compared to
48
49 placebo, however this did not translate into an OS benefit and there were much higher grade
50
51 3/4 adverse event rates in patients on pazopanib, for example, hypertension, neutropenia,
52
53 liver toxicity, diarrhoea, fatigue, thrombocytopenia and palmar-plantar erythema. The dose of
54
55
56
57
58
59
60
61
62
63
64
65

1 pazopanib was reduced in 58%, and 33.3% discontinued treatment secondary to toxicity
2 compared to 5.6% in the placebo arm [25]. Consequently, the drug has not been submitted for
3
4 Market Authorisation.
5
6

7 8 9 **3.2 Nintedanib**

10
11
12
13
14 Nintedanib (BIBF 1120) is a triple angiokinase inhibitor, inhibiting VEGFR, FGFR and
15
16 PDGFR, which all contribute to tumour angiogenesis [26]. Activity of the drug in a
17
18 randomised phase II trial [27] led to a phase III study in first-line therapy.
19
20
21
22
23

24 In the AGO-OVAR 12 nintedanib or placebo was combined with carboplatin and paclitaxel
25
26 and then continued as maintenance for up to 120 weeks. There was a 1.2 month difference in
27
28 median PFS, significantly longer in patients receiving nintedanib compared with placebo but
29
30 this small difference was thought to be insufficient for further development in this indication
31
32 [28]. Hypertension is uncommon with this drug and most of the adverse events were
33
34 gastrointestinal, with 21% of patients in the nintedanib arm experiencing \geq grade 3 diarrhoea
35
36 [28]. Trials continue in patients with ‘platinum-resistant’ ovarian cancer and in patients with
37
38 clear cell tumours of the ovary or endometrium.
39
40
41
42
43
44
45

46 **3.3 Cediranib**

47
48
49
50
51 Cediranib, an oral inhibitor of VEGFR-1, 2 and 3 is also active in recurrent ovarian cancer.
52
53 The magnitude of response of this drug was modest but sufficient for exploration in a phase
54
55 III trial [29]. Cediranib was evaluated in ICON6, an academic-led randomised, three arm,
56
57 double-blind placebo-controlled trial in ‘platinum-sensitive’ ovarian cancer. The design
58
59
60
61
62
63
64
65

1 allowed comparison of the effect of cediranib with chemotherapy, and as maintenance
2 therapy [30]. The original trial design was changed when the manufacturer temporarily
3
4 ceased production of the drug, and the main comparison using a smaller number of patients
5
6 was between chemotherapy and concurrent cediranib followed by maintenance cediranib
7
8 with chemotherapy and placebo throughout. There was a significant improvement in median
9
10 PFS, from 8.7 to 11 months (HR 0.56; $p < 0.0001$). OS data were immature at the time of
11
12 publication. However, toxicity, principally fatigue, diarrhoea and hypertension were
13
14 significant with 32% of patients discontinuing cediranib during treatment. This was most
15
16 evident when cediranib was given with chemotherapy [30]. A submission for Market
17
18 Authorisation in patients was recently withdrawn by the manufacturer. However, cediranib is
19
20 an active drug and continues to be evaluated in ovarian cancer (see below).
21
22
23
24
25
26
27
28

29 **4. Targeting the folate receptor**

30
31
32
33

34 The folate cycle maintains essential metabolic reactions required for rapidly growing cells.
35
36 Once folates enter a cell, they have a crucial role in the biosynthesis of purines and
37
38 thymidine, required for DNA synthesis, repair and methylation [31-34]. The alpha isoform of
39
40 the FR (α FR) transports folates by receptor-mediated endocytosis [35] and is selectively
41
42 overexpressed in a number of solid tumours, including non-mucinous ovarian cancers [36]
43
44
45
46
47
48 Farletuzumab (MORAb-003), a humanised monoclonal antibody to α FR leads to cell-
49
50 mediated cytotoxicity, complement dependent killing and non-immune mediated α FR-
51
52 dependent inhibition of growth under folate limiting conditions [36, 37]. An initial phase II
53
54 study looking at the addition of farletuzumab to chemotherapy followed by maintenance
55
56 therapy in ‘platinum-sensitive’ ovarian cancer showed promising activity with an improved
57
58
59
60
61
62
63
64
65

1 overall response rate compared to historical controls [38]. However, the benefit was not
2 confirmed in a subsequent phase III trial [39].
3
4
5
6

7 In a different folate-targeting strategy, vintafolide (EC145), a folate-conjugated vinca
8 alkaloid that targets FR-expressing cells was explored in a randomised phase II trial in
9 'platinum-resistant' ovarian cancer. In the PRECEDENT trial patients were randomised to
10 PLD alone, or in combination with vintafolide [40]. The study met its primary end point,
11 demonstrating a 2.3 month improvement in median PFS in the experimental arm (5.0 versus
12 2.7 months; HR 0.63; p=.031) but the subsequent randomised phase III trial (PROCEED)
13 [41] was stopped early because a pre-specified interim analysis showed no benefit.
14
15
16
17
18
19
20
21
22
23
24
25

26 **5. Homologous recombination deficiency (HRD) and ovarian cancer**

27
28
29
30

31 Normal cellular function and genomic stability is maintained by recognition and subsequent
32 repair of DNA damage that occurs in all cells [42]. There are 450 known genes implicated in
33 DNA damage response and repair [43] and they are sub-divided into 5 distinct pathways
34 which are responsible for repair of specific types of DNA damage [44]. Double stranded
35 DNA breaks (DSB) are the most lethal insult to the genome and if left unrepaired, genomic
36 instability and cell death will occur [45]. They can be repaired by several different pathways,
37 the main one being homologous recombination repair (HRR). A large proportion of DSB
38 arise during DNA replication when a replication fork encounters an unrepaired single strand
39 break (SSB). The HRR pathway, together with PARP-1, a nuclear enzyme, is especially
40 important in repairing these collapsed replications forks [46, 47]. If HRR is defective (HRD),
41 cells are dependent on alternative pathways for repair. These are significantly impaired by
42 inhibition of PARP enzymes. BRCA1 and BRCA2 proteins play an important role in HRR,
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and when mutated, cells have HRD that can be selectively exploited by PARP inhibitors,
2 leading to unrepaired, or poorly repaired DNA and tumour synthetic lethality [48].
3
4
5
6

7 **6. Ovarian cancer and PARP inhibitors (PARPi)**

8
9

10
11 Germline mutations of BRCA1 and BRCA2 genes are present in about 15% of high-grade
12 serous ovarian cancer (HGSOC), the most common histological subtype. Whilst this is the
13 most common cause of HRD, somatic mutations of the BRCA genes are found in about 5%
14 of these tumours as well as mutations of other key HRR genes, such as RAD51. It has been
15 estimated that approximately 50 % of HGSOC tumours have HRD [49, 50] sometimes
16 referred to as ‘BRCAness’ [51]. Targeting HRD with PARPi, in both BRCA^{mut} (BRCA
17 mutated) and BRCA^{wt} (BRCA wild-type) ovarian cancer is an important therapeutic approach
18 that is being developed in high-grade ovarian cancers. Several oral PARPi are being
19 developed, and are summarised in table 3.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **6.1 Olaparib**

37
38
39
40

41 Much of the initial investigations with PARPi and the greatest body of information comes
42 from studies with olaparib (AZD2281). Frequent and sometimes durable responses were seen
43 in Phase I trials in patients with BRCA^{mut} cancers [52, 53]. Subsequent phase II trials in
44 BRCA^{mut} advanced breast and ovarian cancer confirmed the activity of olaparib monotherapy
45 [54, 55].
46
47
48
49
50
51
52
53
54
55

56 The first randomised trial, Study 12 compared olaparib with PLD in women with a BRCA^{mut}
57 recurrent ovarian cancer [56]. It was a small trial with three arms (two different doses of
58
59
60
61
62
63
64
65

1 olaparib, 200mg bd and 400mg bd,) continuously were compared with PLD (50mg/m² IV)
2 every four weeks in patients with a BRCA^{mut} relapsing ≤ 12 months after prior therapy. There
3
4 was no statistically significant difference in PFS between the olaparib and PLD arms.
5
6
7 Olaparib was active, as predicted but the outcome of patients treated with PLD was better
8
9 than expected and confounded the ability to see a benefit in favour of olaparib [56].
10

11
12
13
14 Clear activity of single-agent olaparib in BRCA^{mut} was also demonstrated in Study 42, a
15
16 multicentre phase II trial that enrolled 298 patients with germline BRCA1/2 mutations and
17
18 recurrent breast, ovarian, pancreatic or prostate cancers [57]. Within this trial there were 193
19
20 patients who had received ≥ 3 lines for chemotherapy for ovarian cancer and the overall
21
22 response rate was 34%, median duration of response 7.9 months [58]. On the basis of these
23
24 data the US FDA granted approval for single agent olaparib in this group.
25
26
27
28
29
30

31 **6.2 Olaparib maintenance therapy**

32
33
34
35

36 Most of the studies with olaparib and other PARPi have focussed on using these drugs as
37
38 maintenance therapy following chemotherapy. The original trial, study 19, included patients
39
40 with platinum-sensitive HGSOC who had responded to platinum-based therapy. The trial was
41
42 designed to investigate maintenance olaparib in a broad setting, including patients with or
43
44 without a BRCA^{mut}. The inclusion of the latter group was based on emerging data showing
45
46 single agent activity of olaparib in patients without a BRCA mutation [59]. Study 19
47
48 randomly assigned 265 patients to olaparib capsules (400mg BD) or placebo within 8 weeks
49
50 of completing platinum-based therapy. There was a significant difference in PFS with
51
52 olaparib compared to placebo, measured from the start of maintenance therapy (8.4 vs 4.8
53
54 months, HR 0.35; p<.001) [60].
55
56
57
58
59
60
61
62
63
64
65

1
2 At study entry, the BRCA mutation status was known for only 98 (37%) of the patients. A
3
4 later analysis of BRCA status in germline and or tumour was carried out and BRCA status
5
6 became available for 254 (96%) of patients. A pre-specified retrospective analysis of all
7
8 efficacy endpoints was done [61]. In the mutated-BRCA (germline or somatic BRCA^{mut})
9
10 group of 136 patients there was an even greater increase in the median PFS from start of
11
12 maintenance with olaparib compared to the placebo group (11.2 vs 4.3 months; HR 0.18;
13
14 p<0.0001). However, there was also a benefit in the BRCA^{wt} group (HR 0.54; p=0.0075).
15
16
17
18
19
20

21 Exploratory end-points such as the time to first subsequent therapy or death (TFST) and time
22
23 to second subsequent therapy or death (TSST) were significantly improved with olaparib
24
25 [61], adding weight to the overall clinical value of this therapy in the absence of a significant
26
27 OS benefit. It is noteworthy that in patients with a BRCA^{mut} the start of the next line of
28
29 therapy was delayed by a median of 9.4 months (median PFS 15.6 versus 6.2 months; HR
30
31 0.32; p<0.0001). In the third interim survival analysis, there is a trend for a survival benefit in
32
33 the BRCA^{mut} group but it does not reach statistical significance (34.9 vs 30.2 months; HR
34
35 0.62; p=0.02). The reasons for this include the small sample size, multiple survival analyses,
36
37 and most importantly crossover to a PARPi by 23% of patients [62]. However, the longer
38
39 follow up at this analysis identified that 13% of all patients (15% of BRCA^{mut} patients)
40
41 received maintenance olaparib for at least 5 years. The most common toxicities, with an
42
43 incidence of ≥10% in the olaparib group, were nausea, vomiting, fatigue and anaemia, most
44
45 of which were grade ≤2 [60].
46
47
48
49
50
51
52
53
54
55

56 Based on the results of this trial, the drug received marketing authorisation as maintenance
57
58 therapy in mutated-BRCA HGSOE from the EMA and many other international regulatory
59
60
61
62
63
64
65

1 authorities. Two phase III trials of olaparib maintenance have now been completed, using
2 tablets, 300mg bd, rather than capsules. SOLO-1 (NCT01844986) recruited patients with
3
4 newly diagnosed BRCA^{mut} ovarian cancer, who responded to first line platinum therapy; the
5
6 results are pending. The top-line results for SOLO-2 (NCT01874353) in BRCA^{mut} high-grade
7
8 ‘platinum-sensitive’ ovarian cancer after ≥ 2 lines of platinum therapy have reported a
9
10 favourable outcome but the results have not yet been presented.
11
12
13
14
15
16

17 **6.3 Olaparib combination with molecularly targeted therapies**

18
19
20
21

22 After showing promising activity in a phase I trial [63], the combination of cediranib with
23
24 olaparib was tested in a phase II trial [64]. Patients with ‘platinum-sensitive’ ovarian cancer
25
26 were randomly assigned to receive olaparib capsules alone (400mg BD) or olaparib (200mg
27
28 BD) and cediranib (30mg od). The trial, without intravenous cytotoxic chemotherapy
29
30 resulted in a significant improvement in PFS in the combination arm. The median PFS was
31
32 17.7 months versus 9.0 months; HR 0.42; p=0.005). A post-hoc analysis suggested the
33
34 greatest benefit was in the subgroup of BRCA^{wt} or unknown. However, 70% of patients in
35
36 the combination arm experienced \geq grade 3 AEs, including diarrhoea, fatigue and
37
38 hypertension. Nevertheless, the encouraging results have led to randomised trials in recurrent
39
40 ovarian cancer, comparing this combination with chemotherapy NRG-GY004
41
42 (NCT02446600), and as maintenance in the planned ICON9 trial. A first-line trial, PAOLA-1
43
44 is comparing the combination of olaparib and bevacizumab to bevacizumab maintenance
45
46 alone following carboplatin/paclitaxel and bevacizumab (NCT02477644).
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

6.4 Niraparib

The recently reported results of the maintenance trial, NOVA using niraparib (MK4827), an active oral, selective PARP1 and 2 inhibitor [65] have confirmed the value of maintenance therapy and added weight to the broader use of PARPi in both germline BRCA^{mut} (gBRCA^{mut}) and non-gBRCA^{mut} HGSOc cohorts who have responded to their most recent platinum-based chemotherapy. The NOVA trial (NCT01847274) is a double-blind controlled phase III maintenance study of niraparib vs placebo and enrolled these two cohorts, randomising patients 2:1 to niraparib 300mg once daily or placebo. In the 203 patients with gBRCA^{mut} niraparib led to a significant prolongation in the PFS (median PFS after enrolment 21 months versus 5.5 months with placebo; HR 0.27; p< 0.001). Similarly, in the 350 non-gBRCA^{mut} patients there was a significant benefit for niraparib (median PFS 3.9 versus 9.3 months; HR 0.45; p<0.001) [66]. In an exploratory analysis, tumours were tested for HRD using the MyChoice assay (Myriad Genetics). Significant benefit in PFS was seen across all subgroups, including somatic BRCA^{mut}, (HRD positive), BRCA^{wt} HRD positive and non-gBRCA^{mut} HRD negative groups. The effect of niraparib was less in HRD negative tumours and it remains to be seen whether the sensitivity of this assay is sufficient for it to distinguish patients who may or may not have a clinically meaningful benefit from niraparib. The most common adverse effects were thrombocytopenia, often occurring early, anaemia and neutropenia, which could usually be managed by dose reductions.

As with olaparib, combination studies of niraparib with bevacizumab have started and there are plans to conduct studies in the first-line setting. The drug has yet to be licensed in ovarian cancer, but the results of the NOVA trial have confirmed the significant benefit of PARPi in

1 the treatment of recurrent ovarian cancer and value of this drug in patients without a germline
2 or somatic BRCA mutation.
3
4
5
6

7 **6.5 Rucaparib**

8
9

10
11 In addition to inhibition of PARP 1 and 2 rucaparib also inhibits other PARP isoforms,
12 tankyrase 1 and 2 (TNKS1/2) [67]. Phase I studies identified 600mg BD as the optimal dose
13 [68] that has been taken forward in ovarian cancer patients. The drug has been given
14 ‘breakthrough’ designation by the FDA for use as a single agent in patients with BRCA^{mut}
15 who have had at least 2 lines of platinum-based chemotherapy [69]. ARIEL 2
16 (NCT01891344), is a phase II study designed to identify patients who are likely to respond to
17 rucaparib, based on biopsies to characterise a biomarker test for HRD that measures the
18 degree of genomic scarring, expressed as Loss of Heterozygosity (LOH), a marker of tumour
19 HRD. Three pre-defined HRD subgroups, tumour BRCA^{mut}, BRCA-like
20 (BRCA^{wt}/LOHhigh) and biomarker negative (BRCA^{wt}/LOHlow) were identified. Two-
21 hundred and six patients were enrolled and the median PFS was 9.4 vs 7.1 vs 3.7 months,
22 with ORR of 82%, 45% and 21% in the BRCA^{mut}, BRCA-like and biomarker negative
23 groups respectively. Robust activity was seen in both germline and somatic BRCA^{mut} patients
24 and the median duration of response was 9.3 months, but is still ongoing [70]. Rucaparib is
25 generally well tolerated, with the most common adverse events being nausea, fatigue and
26 increase in ALT/AST [70]. The HRD algorithm will be applied prospectively to ARIEL 3
27 (NCT01968213), a randomised phase III maintenance study of rucaparib vs placebo in high
28 grade ovarian cancer, BRCA^{mut} or BRCA^{wt} who have responded to ≥ 2 platinum regimens
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

6.6 Veliparib

1
2
3
4
5 Veliparib (ABT-888) is an orally bioavailable small molecule that inhibits PARP1 and 2 and
6
7 is able to penetrate the blood brain barrier [71]. Phase I studies have evaluated its activity in
8
9 combination with cytotoxic chemotherapy, with myelosuppression being the most common
10
11 toxicity [72-74]. Responses were observed in BRCA^{mut} cancers [74]. Single agent veliparib
12
13 is active in BRCA^{mut} recurrent ovarian cancer as shown in a multicentre phase II clinical trial
14
15 [75]. However, a phase II trial conducted to evaluate its activity in combination with oral
16
17 cyclophosphamide in BRCA^{mut} ovarian cancer revealed no improvement in response rate or
18
19 median PFS compared to cyclophosphamide alone [76]. A three-arm phase III placebo
20
21 controlled trial of carboplatin and paclitaxel with placebo, or veliparib followed by
22
23 maintenance placebo, or the combination followed by veliparib maintenance in first line
24
25 treatment of advanced HGSOC is currently recruiting patients (NCT02470585).
26
27
28
29
30
31

6.7 Talazoparib

32
33
34
35
36
37
38
39 Talazoparib (BMN 673) inhibits PARP1/2 and pre-clinical studies have shown it to be more
40
41 potent than other PARPi [77]. In a phase I dose escalation study, responses were seen in
42
43 11/17 BRCA^{mut} ovarian cancers. The recommended dose is 1000mcg/day due to dose-
44
45 limiting thrombocytopenia [78]. A phase II study for single agent talazoparib in patients with
46
47 BRCA^{mut} advanced solid tumours is currently underway (NCT01989546) and importantly,
48
49 the drug is being examined in patients who have previously been treated with a PARPi
50
51 (NCT02326844).
52
53
54
55
56
57
58
59
60
61
62
63
64
65

7. Ovarian cancer and the immune system

1
2
3
4
5 The success of immune checkpoint inhibition in melanoma and lung cancer [79-83] has
6
7 inspired further investigation of these agents in multiple other solid tumours, including
8
9 ovarian cancer. Tumour cells are able to 'escape' the immune system and one of the most
10
11 important components is an immunosuppressive co-signal (immune checkpoint) facilitated by
12
13 programmed cell death 1 (PD-1) and its ligand PDL-1 [84]. PD-1 is mainly expressed on T-
14
15 cells and PDL-1 is expressed on numerous types of cancer cells and on tumour infiltrating
16
17 immune cells in the tumour microenvironment [84]. In ovarian cancer, the presence of
18
19 tumour infiltrating lymphocytes (TILs) is associated with a better outcome [85]. Nivolumab,
20
21 pembrolizumab and avelumab are checkpoint inhibitors being trialled in ovarian cancer.
22
23
24
25
26
27
28

29 Intravenous nivolumab, an anti-PD-1 antibody was given to 20 patients with 'platinum-
30
31 resistant' ovarian cancer using either 1mg/kg or 3mg/kg two-weekly infusions. The overall
32
33 response rate was 15%. No correlation was found between clinical response and PDL-1
34
35 expression [86].
36
37
38
39
40

41 A phase Ib trial with the humanized monoclonal anti-PD-1 antibody, pembrolizumab
42
43 included patients with ovarian cancer (KEYNOTE-028) (NCT02054806). In PDL-1+ve
44
45 (PDL-1 expression \geq 1%) there were 26 patients with advanced ovarian cancer and the
46
47 overall response rate was 11.5% [87]. Pembrolizumab is undergoing further evaluation in a
48
49 phase II trial in ovarian cancer (KEYNOTE-100) (NCT02674061).
50
51
52
53
54
55

56 Avelumab (MSB0010718C), a fully human anti-PDL-1 antibody, has been evaluated in the
57
58 JAVELIN Solid tumour phase Ib study (NCT01772004). One hundred and twenty-four
59
60
61
62
63
64
65

1 unselected patients with heavily pre-treated ‘platinum-resistant’ ovarian cancer patients were
2 enrolled, making this the largest reported dataset of patients with ovarian cancer and immune
3 checkpoint inhibitors. The overall response rate was 9.7% [88]. The most common
4 treatment related adverse events were fatigue, nausea/vomiting, diarrhoea/constipation, chills,
5 infusion-related reactions, rash and hypothyroidism. Whilst tumour response rates are
6 modest, some patients experience long responses to all these checkpoint inhibitors. Phase III
7 trials with avelumab in ovarian cancer are currently underway. JAVELIN Ovarian 200
8 (NCT02580058) is a trial of avelumab +/- PLD vs PLD alone in ‘platinum-resistant’ ovarian
9 cancer and JAVELIN Ovarian 100 (NCT02718417) is a three-arm trial evaluating avelumab
10 in combination with and/or following first line chemotherapy for advanced ovarian cancer.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **9. Phosphatidylinositol 3-Kinase (PI3K) inhibitors**

26
27
28
29 The PI3K/AKT/mTOR is a complex pathway that regulates a number of crucial cellular
30 functions, including cell growth, migration, survival and angiogenesis [89]. Changes in the
31 pathway and molecular alterations, such as gene mutations and amplifications contribute to
32 oncogenesis and resistance to anti-cancer drugs. It is an important therapeutic target in
33 cancer, however, there has been little success of these agents in ovarian cancer to date [90].
34
35
36
37
38
39
40
41
42

43 **10. Wee1 inhibitors**

44
45
46 When DNA is damaged, there are various checkpoints that arrest the cell cycle to allow for
47 this damage to be repaired. The G1 checkpoint is mainly regulated by the p53, which is
48 commonly mutated in cancer cells. p53-deficient tumours therefore rely on the G2/S
49 checkpoint for DNA damage repair [91]. If the G2 checkpoint is impeded, then p53 deficient
50 cells may become more sensitive to DNA-damaging drugs [92]. Wee1 is a tyrosine kinase
51 that phosphorylates CDC2, which inactivates the CDC2/cyclin B complex required for the
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 normal functioning of the G2 checkpoint. AZD1775 (formally MK-1775) is a potent Wee1
2 inhibitor. In combination with carboplatin, it has been shown to have promising activity in
3
4 'platinum-resistant' disease (relapse <3 months following completion of first line therapy)
5
6 with p53 mutations. The most common toxicities reported were myelosuppression, fatigue,
7
8 diarrhoea, nausea and vomiting [93].
9
10

11. Summary

11
12
13
14
15
16
17 This review highlights the paradigm shift in the treatment of ovarian cancer. Although
18
19 chemotherapy remains the backbone of treatment, novel targeted therapies, both in
20
21 combination with chemotherapy and alone, have demonstrated significant improvements in
22
23 PFS and the 'one size fits all' treatment approach for ovarian cancer is no longer applicable.
24
25 Bevacizumab and olaparib are two drugs directed against the angiogenic and DNA damage
26
27 response pathways that have been approved for treatment of ovarian cancer. Olaparib is the
28
29 first drug directed against a predictive marker which allows the selection of patients likely to
30
31 achieve the greatest benefit. Encouraging results are emerging from studies with other PARP
32
33 inhibitors and these are likely to widen the use of these drugs in ovarian cancer. A benefit is
34
35 seen not only in patients with a BRCA mutation, but also in a larger number of patients
36
37 within an HRD positive group. Combinations of PARP inhibitors with other molecularly
38
39 targeted therapies, especially anti-angiogenic drugs are also showing promise. The most
40
41 recent development in therapeutics has been investigation of immune checkpoint inhibitors.
42
43 Their role in treatment of ovarian cancer is unclear, but many trials are in progress and there
44
45 is hope that the benefit of these drugs seen in other tumours may extend into the treatment of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1: Phase III trials of bevacizumab in advanced ovarian cancer.

Study	Population	Treatment	Median PFS (months)	Median OS (months)
ICON7 [9]	First-line high risk stage I-IIA or stage IIB-IV ovarian cancer (n=1528)	CP vs CP + bevacizumab (7.5mg/kg) followed by maintenance bevacizumab	22.4 vs 24.1 (HR 0.87; p=0.04)	58.6 vs 58.0 (p=0.85) Poor prognosis group: 30.2 vs 39.7 (p=0.03)
GOG 218 [10]	First-line stage III (incompletely resected) and stage IV ovarian cancer (n=1873)	CP vs CP + bevacizumab (15mg/kg) + maintenance + PL vs CP + bevacizumab (15mg/kg) + maintenance bevacizumab	10.3 vs 11.2 vs 14.1 (HR 0.72; p<0.001)	39.3 vs 38.7 vs 39.7 (HR 0.95; p=0.45)
OCEANS [13]	PSROC (n=484)	GC + PL vs GC + bevacizumab (15mg/kg)	8.4 vs 12.4 (HR 0.48; p<.0001)	32.9 vs 33.6 (HR 0.95; p=0.65)
GOG 0213 [14]	PSROC (n=674)	CP vs CP + bevacizumab (15mg/kg)	10.4 vs 13.8 (HR 0.61; p<.0001)	37.7 vs 42.2 (HR 0.83; p=0.056)
AURELIA [15]	PRROC (n= 361)	CT vs CT + bevacizumab (10mg/kg q2/52 or 15mg/kg q3/52)	3.4 vs 6.7 (HR 0.48; p<.001)	13.3 vs 16.6 (HR 0.85; p<.174)

PSROC – ‘platinum-sensitive’ recurrent ovarian cancer; PRROC – ‘platinum-resistant recurrent’ ovarian cancer; CP – carboplatin/paclitaxel;

PL – placebo; GC – gemcitabine/carboplatin; CT – chemotherapy [choice of weekly paclitaxel, PLD, topotecan];

q2/52 – 2 weekly; q3/52 – 3 weekly;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2: VEGFR-Inhibitors in ovarian cancer

Agent	Trial	Line of treatment	PFS (months)
Sorafenib	Randomised phase II [94] CP +/- sorafenib followed by maintenance sorafenib for a total of 1yr	First line	15.4 vs 16.3 (p=0.38)
Pazopanib	Randomised Phase II: MITO 11 [24] Pazopanib + paclitaxel vs paclitaxel alone Phase III maintenance study: AGO-OVAR-16 [25] Pazopanib v placebo maintenance	PRROC First line	6.3 vs 3.4 17.9 vs 12.3 HR 0.77; p=0.0021
Nintedanib	Phase III: AGO-OVAR-12 [28] CP +/- nintedanib followed by maintenance nintedinib or placebo	First line	17.2 vs 16.6 HR 0.84; p=0.024
Cediranib	Phase III: ICON 6 [30] 3 arm study: CT with placebo vs CT + cediranib followed by placebo maintenance vs CT + cediranib followed by cediranib maintenance	First relapse PSROC	11.0 vs 8.7 HR 0.56; p<0.0001

CP – carboplatin /paclitaxel; CT – platinum-based chemotherapy; PRROC – ‘platinum-resistant’ recurrent ovarian cancer;

PSROC – ‘platinum-sensitive’ recurrent ovarian cancer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3: PARPi trials in ovarian cancer (results awaited)

Agent	Trial	Population	Line of treatment
Olaparib (Astrazeneca)	SOLO-1 (NCT01844986) : Phase III maintenance (olaparib vs placebo)	BRCA ^{mut} ; AOC	First line
	SOLO-2 (NCT01874353) : Phase III maintenance (olaparib vs placebo)	BRCA ^{mut} ; PSROC	After ≥2 lines platinum based CT
	SOLO-3 (NCT02282020) : Phase III olaparib vs physician choice CT (standard of care non-platinum based)	BRCA ^{mut} ; PSROC	After ≥2 lines of platinum based CT
Rucaparib (Clovis)	ARIEL 2 (part 2) (NCT01891344) : Single arm study	HGROC	Received ≥2 prior lines of CT
	ARIEL 3 (NCT01968213) : Phase III maintenance (rucaparib vs placebo)	HGROC	After ≥2 lines of platinum based CT
	ARIEL 4 (NCT02855944) : Phase III rucaparib vs chemotherapy	BRCA ^{mut} ; ROC	Received ≥2 lines prior CT
Niraparib (Tesar)	QUADRA study (NCT02354586) : Single arm phase II study	HGROC	Must have had 3/4 prior lines of CT
	PRIMA study (NCT02655016) : Phase III maintenance (niraparib vs placebo)	HRD +ve; AOC	First line
	AVANOVA study (NCT02354131) : Phase I/II niraparib +/- bevacizumab	HRD+ve; PSROC	No limits on number of previous lines of CT
Veliparib (AbbVie)	Phase III combination CT followed by maintenance (NCT02470585)	BRCA ^{mut} ; AOC	First line
Talazoparib (Medivation/ Pfizer)	Phase I/II study (NCT01989546)	BRCA ^{mut} solid tumours	After ≥ 1 standard CT <u>OR</u> no standard Rx options
	Phase II study (NCT02326844)	gBRCA ^{mut} ; ROC	Progression following a PARPi

CT – chemotherapy; Ph – phase; gBRCA^m – germline BRCA mutation; PSROC – ‘platinum sensitive’ recurrent ovarian cancer; HGROC – high grade recurrent ovarian cancer; HRD – homologous recombination deficient; AOC – advanced ovarian cancer; Rx – treatment

References:

1. Siegel, R.L., K.D. Miller, and A. Jemal, *Cancer statistics, 2015*. CA: a cancer journal for clinicians, 2015. **65**(1): p. 5-29.
2. Folkman, J., *Anti-angiogenesis: new concept for therapy of solid tumors*. Annals of surgery, 1972. **175**(3): p. 409.
3. Schmid, B.C. and M.K. Oehler, *Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers*. Current treatment options in oncology, 2015. **16**(1): p. 1-14.
4. Burger, R.A., *Overview of anti-angiogenic agents in development for ovarian cancer*. Gynecologic oncology, 2011. **121**(1): p. 230-238.
5. Alvarez, A.A., et al., *The prognostic significance of angiogenesis in epithelial ovarian carcinoma*. Clinical Cancer Research, 1999. **5**(3): p. 587-591.
6. Kumaran, G.C., G.C. Jayson, and A.R. Clamp, *Antiangiogenic drugs in ovarian cancer*. Br J Cancer, 2009. **100**(1): p. 1-7.
7. Ferrara, N. and R.S. Kerbel, *Angiogenesis as a therapeutic target*. Nature, 2005. **438**(7070): p. 967-974.
8. Jain, R.K., *Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy*. Science, 2005. **307**(5706): p. 58-62.
- * 9. Perren, T.J., et al., *A phase 3 trial of bevacizumab in ovarian cancer*. The New England journal of medicine, 2011. **365**(26): p. 2484-2496.
10. Burger, R.A., et al., *Incorporation of bevacizumab in the primary treatment of ovarian cancer*. N Engl J Med, 2011. **365**(26): p. 2473-83.
11. Oza, A.M., et al., *Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial*. Lancet Oncol, 2015.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- * 12. Aghajanian, C., et al., *OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer*. J Clin Oncol, 2012. **30**(17): p. 2039-2045.
 - 13. Aghajanian, C., et al., *Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer*. Gynecologic oncology, 2015. **139**(1): p. 10-16.
 - 14. Coleman, R., et al., *A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)*. Gynecologic Oncology, 2015. **137**: p. 3-4.
 - * 15. Pujade-Lauraine, E., et al., *Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial*. Journal of clinical oncology, 2014. **32**(13): p. 1302-1308.
 - 16. Stockler, M.R., et al., *Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer*. Journal of Clinical Oncology, 2014. **32**(13): p. 1309-1316.
 - 17. Poveda, A.M., et al., *Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial*. J Clin Oncol, 2015. **33**(32): p. 3836-8.

18. Tew, W.P., et al., *Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study*. *Cancer*, 2014. **120**(3): p. 335-343.
19. Coleman, R.L., et al., *Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer*. *Journal of Clinical Oncology*, 2011. **1**).
20. Gotlieb, W.H., et al., *Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study*. *The lancet oncology*, 2012. **13**(2): p. 154-162.
21. Monk, B.J., et al., *Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial*. *The Lancet Oncology*, 2014. **15**(8): p. 799-808.
22. Eichbaum, M., et al., *The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer*. *BMC Cancer*, 2011. **11**: p. 453.
23. Petrillo, M., et al., *Targeting the hallmarks of ovarian cancer: The big picture*. *Gynecologic oncology*, 2016.
24. Pignata, S., et al., *Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial*. *Lancet Oncol*, 2015. **16**(5): p. 561-8.
25. du Bois, A., et al., *Incorporation of pazopanib in maintenance therapy of ovarian cancer*. *Journal of Clinical Oncology*, 2014. **32**(30): p. 3374-3382.
26. Hilberg, F., et al., *BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy*. *Cancer Res*, 2008. **68**(12): p. 4774-82.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
27. Ledermann, J.A., et al., *Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer*. J Clin Oncol, 2011. **29**(28): p. 3798-804.
 28. du Bois, A., et al., *Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial*. Lancet Oncol, 2016. **17**(1): p. 78-89.
 29. Matulonis, U.A., et al., *Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer*. J Clin Oncol, 2009. **27**(33): p. 5601-6.
 30. Ledermann, J.A., et al., *Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial*. Lancet, 2016. **387**(10023): p. 1066-74.
 31. Ledermann, J., S. Canevari, and T. Thigpen, *Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments*. Annals of Oncology, 2015: p. mdv250.
 32. Gonen, N. and Y.G. Assaraf, *Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance*. Drug Resistance Updates, 2012. **15**(4): p. 183-210.
 33. Elnakat, H. and M. Ratnam, *Role of folate receptor genes in reproduction and related cancers*. Frontiers in bioscience: a journal and virtual library, 2005. **11**: p. 506-519.
 34. Zwicke, G.L., G.A. Mansoori, and C.J. Jeffery, *Utilizing the folate receptor for active targeting of cancer nanotherapeutics*. Nano Reviews & Experiments, 2012. **3**.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
35. Yap, T.A., C.P. Carden, and S.B. Kaye, *Beyond chemotherapy: targeted therapies in ovarian cancer*. Nat Rev Cancer, 2009. **9**(3): p. 167-81.
 36. Kalli, K.R., et al., *Folate receptor alpha as a tumor target in epithelial ovarian cancer*. Gynecol Oncol, 2008. **108**(3): p. 619-26.
 37. Ebel, W., et al., *Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha*. Cancer Immun, 2007. **7**: p. 6.
 38. Armstrong, D.K., et al., *Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer*. Gynecologic Oncology, 2013. **129**(3): p. 452-458.
 39. Vergote, I., et al., *A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse*. Journal of Clinical Oncology, 2016: p. JCO632596.
 40. Naumann, R.W., et al., *PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer*. Journal of Clinical Oncology, 2013. **31**(35): p. 4400-4406.
 41. Oza, A., et al., *A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED)(NCT01170650)*. Gynecologic Oncology, 2015. **137**: p. 5-6.
 42. Hoeijmakers, J.H., *DNA damage, aging, and cancer*. N Engl J Med, 2009. **361**(15): p. 1475-85.
 43. Pearl, L.H., et al., *Therapeutic opportunities within the DNA damage response*. Nat Rev Cancer, 2015. **15**(3): p. 166-180.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
44. Ciccia, A. and S.J. Elledge, *The DNA damage response: making it safe to play with knives*. Mol Cell, 2010. **40**(2): p. 179-204.
 45. Huertas, P., *DNA resection in eukaryotes: deciding how to fix the break*. Nat Struct Mol Biol, 2010. **17**(1): p. 11-16.
 46. Arnaudeau, C., C. Lundin, and T. Helleday, *DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells1*. Journal of Molecular Biology, 2001. **307**(5): p. 1235-1245.
 47. Bryant, H.E., et al., *PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination*. The EMBO Journal, 2009. **28**(17): p. 2601-2615.
 48. Ashworth, A., *A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair*. Journal of Clinical Oncology, 2008. **26**(22): p. 3785-3790.
 49. Network, C.G.A.R., *Integrated genomic analyses of ovarian carcinoma*. Nature, 2011. **474**(7353): p. 609-615.
 50. Pennington, K.P., et al., *Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas*. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. **20**(3): p. 764-775.
 51. Turner, N., A. Tutt, and A. Ashworth, *Hallmarks of 'BRCAness' in sporadic cancers*. Nat Rev Cancer, 2004. **4**(10): p. 814-9.
 52. Fong, P.C., et al., *Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers*. N Engl J Med, 2009. **361**(2): p. 123-34.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
53. Fong, P.C., et al., *Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.* J Clin Oncol, 2010. **28**(15): p. 2512-9.
 54. Audeh, M.W., et al., *Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.* Lancet, 2010. **376**(9737): p. 245-51.
 55. Tutt, A., et al., *Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.* The Lancet, 2010. **376**(9737): p. 235-244.
 56. Kaye, S.B., et al., *Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.* J Clin Oncol, 2012. **30**(4): p. 372-9.
 57. Kaufman, B., et al., *Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.* J Clin Oncol, 2015. **33**(3): p. 244-50.
 58. Domchek, S.M., et al., *Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.* Gynecologic oncology, 2016. **140**(2): p. 199-203.
 59. Gelmon, K.A., et al., *Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.* Lancet Oncol, 2011. **12**(9): p. 852-861.
 - * 60. Ledermann, J., et al., *Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.* N Engl J Med, 2012. **366**(15): p. 1382-92.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
61. Ledermann, J., et al., *Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial*. *Lancet Oncol*, 2014. **15**(8): p. 852-61.
 - * 62. Ledermann, J.A., et al., *Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial*. *The lancet oncology*, 2016. **0**(0).
 63. Liu, J.F., et al., *A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer*. *Eur J Cancer*, 2013. **49**(14): p. 2972-2978.
 64. Liu, J.F., et al., *Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study*. *Lancet Oncol*, 2014. **15**(11): p. 1207-14.
 65. Sandhu, S.K., et al., *The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial*. *The lancet oncology*, 2013. **14**(9): p. 882-892.
 - * 66. Mirza, M.R., et al., *Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer*. *The New England journal of medicine*, 2016.
 67. Ledermann, J.A., Y. Drew, and R.S. Kristeleit, *Homologous recombination deficiency and ovarian cancer*. *Eur J Cancer*, 2016. **60**: p. 49-58.
 68. Kristeleit, R.S., et al. *Phase 1/2 study of oral rucaparib: Final phase 1 results*. in *ASCO Annual Meeting Proceedings*. 2014.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
69. Kristeleit, R., et al., *Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOc) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)*. ESMO 2016 Congress.
 70. McNeish, I., et al., *Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis*. J Clin Oncol, 2015. **33**: p. suppl; abstr 5508.
 71. Donawho, C.K., et al., *ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models*. Clinical cancer research, 2007. **13**(9): p. 2728-2737.
 72. Tan, A., et al. *Phase I trial of veliparib,(ABT-888), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors*. in ASCO Annual Meeting Proceedings. 2011.
 73. Kummar, S., et al., *Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas*. Cancer research, 2011. **71**(17): p. 5626-5634.
 74. Kummar, S., et al., *A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas*. Clinical Cancer Research, 2012. **18**(6): p. 1726-1734.
 75. Coleman, R.L., et al., *A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study*. Gynecologic oncology, 2015. **137**(3): p. 386-391.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
76. Kummar, S., et al., *Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer*. *Clinical Cancer Research*, 2015. **21**(7): p. 1574-1582.
 77. Shen, Y., et al., *BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency*. *Clin Cancer Res*, 2013. **19**(18): p. 5003-15.
 78. De Bono, J.S., et al. *First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors*. in *ASCO Annual Meeting Proceedings*. 2013.
 79. Robert, C., et al., *Nivolumab in previously untreated melanoma without BRAF mutation*. *New England journal of medicine*, 2015. **372**(4): p. 320-330.
 80. Weber, J.S., et al., *Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial*. *The lancet oncology*, 2015. **16**(4): p. 375-384.
 81. Robert, C., et al., *Pembrolizumab versus ipilimumab in advanced melanoma*. *New England Journal of Medicine*, 2015. **372**(26): p. 2521-2532.
 82. Brahmer, J., et al., *Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer*. *New England Journal of Medicine*, 2015. **373**(2): p. 123-135.
 83. Borghaei, H., et al., *Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer*. *New England Journal of Medicine*, 2015. **373**(17): p. 1627-1639.
 84. Hamanishi, J., et al., *PD-1/PD-L1 blockade in cancer treatment: perspectives and issues*. *International journal of clinical oncology*, 2016: p. 1-12.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
85. Zhang, L., et al., *Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer*. N Engl J Med, 2003. **348**(3): p. 203-13.
 86. Hamanishi, J., et al., *Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer*. Journal of Clinical Oncology, 2015: p. JCO. 2015.62. 3397.
 87. Varga, A., et al. *Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study*. in *ASCO Annual Meeting Proceedings*. 2015.
 88. Disis, M.L., et al. *Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity*. in *ASCO Annual Meeting Proceedings*. 2016.
 89. Rodon, J., et al., *Development of PI3K inhibitors: lessons learned from early clinical trials*. Nature reviews Clinical oncology, 2013. **10**(3): p. 143-153.
 90. Cheaib, B., A. Auguste, and A. Leary, *The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges*. Chinese journal of cancer, 2015. **34**(1): p. 4.
 91. Do, K., J.H. Doroshow, and S. Kummar, *Wee1 kinase as a target for cancer therapy*. Cell cycle, 2013. **12**(19): p. 3348-3353.
 92. Hirai, H., et al., *Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents*. Molecular cancer therapeutics, 2009. **8**(11): p. 2992-3000.
 93. Leijen, S., et al. *Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (< 3 months) to standard first line therapy*. in *ASCO Annual Meeting Proceedings*. 2015.

94. Hainsworth, J.D., et al., *Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute*. *Cancer medicine*, 2015. 4(5): p. 673-681.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1: Phase III trials of bevacizumab in advanced ovarian cancer.

Study	Population	Treatment	Median PFS (months)	Median OS (months)
ICON7 [9]	First-line high risk stage I-IIA or stage IIB-IV ovarian cancer (n=1528)	CP vs CP + bevacizumab (7.5mg/kg) followed by maintenance bevacizumab	22.4 vs 24.1 (HR 0.87; p=0.04)	58.6 vs 58.0 (p=0.85) Poor prognosis group: 30.2 vs 39.7 (p=0.03)
GOG 218 [10]	First-line stage III (incompletely resected) and stage IV ovarian cancer (n=1873)	CP vs CP + bevacizumab (15mg/kg) + maintenance + PL vs CP + bevacizumab (15mg/kg) + maintenance bevacizumab	10.3 vs 11.2 vs 14.1 (HR 0.72; p<0.001)	39.3 vs 38.7 vs 39.7 (HR 0.95; p=0.45)
OCEANS [13]	PSROC (n=484)	GC + PL vs GC + bevacizumab (15mg/kg)	8.4 vs 12.4 (HR 0.48; p<.0001)	32.9 vs 33.6 (HR 0.95; p=0.65)
GOG 0213 [14]	PSROC (n=674)	CP vs CP + bevacizumab (15mg/kg)	10.4 vs 13.8 (HR 0.61; p<.0001)	37.7 vs 42.2 (HR 0.83; p=0.056)
AURELIA [15]	PRROC (n= 361)	CT vs CT + bevacizumab (10mg/kg q2/52 or 15mg/kg q3/52)	3.4 vs 6.7 (HR 0.48; p<.001)	13.3 vs 16.6 (HR 0.85; p<.174)

PSROC – ‘platinum-sensitive’ recurrent ovarian cancer; PRROC – ‘platinum-resistant recurrent’ ovarian cancer; CP – carboplatin/paclitaxel;

PL – placebo; GC – gemcitabine/carboplatin; CT – chemotherapy [choice of weekly paclitaxel, PLD, topotecan];

q2/52 – 2 weekly; q3/52 – 3 weekly;

Table 2: VEGFR-Inhibitors in ovarian cancer

Agent	Trial	Line of treatment	PFS (months)
Sorafenib	Randomised phase II [94] CP +/- sorafenib followed by maintenance sorafenib for a total of 1yr	First line	15.4 vs 16.3 (p=0.38)
Pazopanib	Randomised Phase II: MITO 11 [24] Pazopanib + paclitaxel vs paclitaxel alone Phase III maintenance study: AGO-OVAR-16 [25] Pazopanib v placebo maintenance	PRROC First line	6.3 vs 3.4 17.9 vs 12.3 HR 0.77; p=0.0021
Nintedanib	Phase III: AGO-OVAR-12 [28] CP +/- nintedanib followed by maintenance nintedinib or placebo	First line	17.2 vs 16.6 HR 0.84; p=0.024
Cediranib	Phase III: ICON 6 [30] 3 arm study: CT with placebo vs CT + cediranib followed by placebo maintenance vs CT + cediranib followed by cediranib maintenance	First relapse PSROC	11.0 vs 8.7 HR 0.56; p<0.0001

CP – carboplatin /paclitaxel; CT – platinum-based chemotherapy; PRROC – ‘platinum-resistant’ recurrent ovarian cancer;

PSROC – ‘platinum-sensitive’ recurrent ovarian cancer

Table 3: PARPi trials in ovarian cancer (results awaited)

Agent	Trial	Population	Line of treatment
Olaparib (Astrazeneca)	SOLO-1 (NCT01844986) : Phase III maintenance (olaparib vs placebo)	BRCA ^{mut} ; AOC	First line
	SOLO-2 (NCT01874353) : Phase III maintenance (olaparib vs placebo)	BRCA ^{mut} ; PSROC	After ≥2 lines platinum based CT
	SOLO-3 (NCT02282020) : Phase III olaparib vs physician choice CT (standard of care non-platinum based)	BRCA ^{mut} ; PSROC	After ≥2 lines of platinum based CT
Rucaparib (Clovis)	ARIEL 2 (part 2) (NCT01891344) : Single arm study	HGROC	Received ≥2 prior lines of CT
	ARIEL 3 (NCT01968213) : Phase III maintenance (rucaparib vs placebo)	HGROC	After ≥2 lines of platinum based CT
	ARIEL 4 (NCT02855944) : Phase III rucaparib vs chemotherapy	BRCA ^{mut} ; ROC	Received ≥2 lines prior CT
Niraparib (Tesarco)	QUADRA study (NCT02354586) : Single arm phase II study	HGROC	Must have had 3/4 prior lines of CT
	PRIMA study (NCT02655016) : Phase III maintenance (niraparib vs placebo)	HRD +ve; AOC	First line
	AVANOVA study (NCT02354131) : Phase I/II niraparib +/- bevacizumab	HRD+ve; PSROC	No limits on number of previous lines of CT
Veliparib (AbbVie)	Phase III combination CT followed by maintenance (NCT02470585)	BRCA ^{mut} ; AOC	First line
Talazoparib (Medivation/ Pfizer)	Phase I/II study (NCT01989546)	BRCA ^{mut} solid tumours	After ≥ 1 standard CT <u>OR</u> no standard Rx options
	Phase II study (NCT02326844)	gBRCA ^{mut} ; ROC	Progression following a PARPi

CT – chemotherapy; Ph – phase; gBRCA^m – germline BRCA mutation; PSROC – ‘platinum sensitive’ recurrent ovarian cancer; HGROC – high grade recurrent ovarian cancer; HRD – homologous recombination deficient; AOC – advanced ovarian cancer; Rx – treatment

PRACTICE POINTS:

- Bevacizumab is licensed for use in ovarian cancers. Variation in precise indications in the ovarian cancer treatment pathway exist in different parts of the world but the drug will increase tumour response rate and extend progression-free survival.
- There are no predictive markers for benefit but one trial, ICON7 in the first-line setting demonstrated a survival benefit in patients with a poorer prognosis.
- In 'platinum-resistant' disease, the addition of bevacizumab to chemotherapy improves the tumour response rate, progression-free survival and patient-reported outcomes.
- BRCA mutations are the first predictive markers for response to PARP inhibitors in ovarian cancer. Olaparib is the first-in-class drug to be licensed for the treatment of ovarian cancer as maintenance therapy in platinum-sensitive ovarian cancer with a BRCA mutation.
- In USA the drug is licensed as a single agent, in patients with a BRCA mutation who have received ≥ 3 lines of chemotherapy

RESEARCH AGENDA:

There has been a rapid expansion of new drugs targeting tumour cell growth and survival pathways. Whilst chemotherapy continues to be a valuable therapeutic approach, the incorporation of these new molecularly targeted drugs into treatment is a research priority

This will involve:

- Having a better understanding of the pathway control mechanisms
- Developing trials to evaluate activity rapidly, using newer endpoints. Dose escalation is being replaced by target activation and novel response endpoints
- Identification of markers predictive of response is a priority
- Molecularly targeted agents, sequentially or in combination are likely to be most effective and designing trials to evaluate these are challenging

Multiple Choice Questions:

1. Which of the following statements about bevacizumab are true:
 - a. It is a fusion protein that binds to VEGF
 - b. Has been shown to improve progression free survival in women with high risk disease when given in combination with first line chemotherapy followed by 12 months maintenance therapy
 - c. Trials failed to show benefit in 'platinum-resistant' recurrent ovarian cancer
 - d. Toxicities of bevacizumab include increased risk of bowel perforation, fistulae formation, impaired wound healing, increased risk of thromboembolism and hypertension
 - e. Measurement of predictive markers allow the selection of patients who will benefit.

Answers:

a) F – bevacizumab is a recombinant monoclonal antibody that binds to circulating VEGF-A; Aflibercept is a fusion protein that binds to VEGF preventing it from binding to its receptors

b) T – ICON7 and GOG 218 are the two key first-line studies investigating the addition of bevacizumab to chemotherapy following surgery. High-risk disease is defined as incomplete cytoreductive surgery (>1cm residual disease) or FIGO stage IV disease. PFS for this population was 14.5 months in the chemotherapy alone arm vs 18.1 months in the chemotherapy plus bevacizumab arm. No OS benefit was seen in these trials.

c) F – AURELIA study adding bevacizumab to chemotherapy in ‘platinum-resistant’ relapse showed significant improvement in tumour response rate, progression free survival and patient-reported outcome.

d) T – these are the main toxicities of all VEGF inhibitors. It is important to carefully select patients for treatment with bevacizumab as those with extensive serosal disease are at high risk of bowel perforation.

e) F – There are no predictive markers to select which patients will benefit.

2. Which of the following are considered to be novel targets in ovarian cancer?
- a. Oestrogen and progesterone receptors
 - b. Folate receptor
 - c. Wee 1
 - d. BRAF
 - e. PARP

Answers:

- a) F – oestrogen and progesterone receptors are targets for inhibition in the treatment of breast cancer. Tamoxifen and aromatase inhibitors can be used in the treatment of ovarian cancer, particularly low-grade serous cancers. However, it is unclear whether oestrogen/progesterone receptor status in these tumours influences the benefit of these drugs

- b) *T – Farletuzumab and vintafolide both target the folate receptor and have been evaluated in the treatment of ovarian cancer. However, they have not been shown to improve survival.*
- c) *T - Wee1 is a tyrosine kinase that is required for normal functioning of the G2 checkpoint in the cell cycle. Wee1 inhibitors, when combined with carboplatin, have shown promising activity in 'platinum-resistant' ovarian cancer with p53 mutations.*
- d) *F – BRAF mutations lead to activation of the MAPK signalling pathway and are commonly found in a number of cancers. BRAF inhibitors are approved in the treatment of malignant melanoma and are being investigated in clinical trials for other BRAF-mutant cancers. BRAF inhibitors are currently not being evaluated in the treatment of ovarian cancer.*
- e) *T – Poly ADP ribose polymerase (PARP) is an enzyme involved in DNA damage repair. PARP inhibitors have been shown improve outcomes in ovarian cancers with homologous recombination deficiency, particularly those with BRCA mutations.*

3. Which of the following statements related to homologous recombination deficiency (HRD) in ovarian cancer are true?
- a. Single strand DNA breaks are the most lethal insult to the genome
 - b. Germline BRCA mutations are present in 50% of high grade serous ovarian cancer
 - c. Olaparib only improves PFS in BRCA mutated ovarian cancer, but has no activity in BRCA^{wt} cancer
 - d. PARP inhibitors are well tolerated, with the most common toxicities being nausea, vomiting, fatigue and anaemia
 - e. The most evidence for the use of PARP inhibitors is in the 'platinum- sensitive' setting

Answers:

- a) *F – Double strand DNA breaks (DSB) are the most lethal insult to the genome and if left unrepaired, cell death will occur.*
- b) *F – germline BRCA mutations are found in 10-15% of high-grade serous ovarian cancers. Approximately 50% of high-grade serous tumours have HRD and behave like BRCA mutated cancer ('BRCAness')*
- c) *F – study 19 is the original trial evaluating the use of olaparib as maintenance therapy in high-grade serous ovarian cancer after completion of platinum based*

therapy. BRCA status was unknown at the time of study entry, but was analysed retrospectively in a pre-specified analysis. In the BRCA mutated (germline or somatic) group of patients, the median PFS was significantly longer in the olaparib group compared to the placebo group. However, there was also a benefit seen in the BRCA wild-type group.

d) T – PARP inhibitors are oral tablets, which are generally well tolerated.

e) T

4. The role of immunotherapy in ovarian cancer is currently being evaluated in multiple trials. Which of the following statements are true?

- a. PD-1 and PDL-1 enable cancer cells to 'escape' the immune system
- b. Tumour infiltrating cells are poor prognostic indicators in ovarian cancer
- c. Pembrolizumab is a humanized monoclonal anti-PD-1 antibody,
- d. Immune checkpoint inhibitors have shown encouraging response rates of > 20% in patients with 'platinum-sensitive' recurrent ovarian cancer
- e. Common adverse events include fatigue, flu-like symptoms, infusion-related reactions, rash and hypothyroidism.

Answers:

- a) T - Tumour cells are able to 'escape' the immune system and one of the most important components is an immunosuppressive co-signal (immune checkpoint) facilitated by programmed cell death 1 (PD-1) and it's ligand PDL-1*
- b) F - In ovarian cancer, the presence of tumour infiltrating lymphocytes (TILs) is prognostic for better survival; a high number of immunosuppressive regulatory T-cells (Tregs) are associated with a poor prognosis*
- c) T - Pembrolizumab and nivolumab are anti-PD-1 antibodies and avelumab is a fully humanised anti-PDL-1 antibody*

d) *F – The JAVELIN Solid tumour phase Ib (avelumab) study in multiple tumours reported an overall response rate of 9.7% in patients with heavily pre-treated ‘platinum-resistant’ ovarian cancer. KEYNOTE-028 study with pembrolizumab reported an overall response rate of 11.5%.*

e) *T*